Omeros | OMER - Interest Expense On Debt


Omeros reported $4.05M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
Adma Biologics USD 3.42M 1.32M Jun/2026
Alnylam Pharmaceuticals USD -84.37M 166.42M Sep/2026
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Cytokinetics USD 38.48M 3.65M Sep/2026
Gilead Sciences USD 269M 22M Sep/2026
Heron Therapeutics USD 600K 100K Dec/2024
Immunic 197K 222K Dec/2025
Insmed USD 20.41M 1.57M Sep/2026
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
MacroGenics USD 4.4M 493K Jun/2026
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 112.4M 108.78M Sep/2026
Pfizer USD 662M 5M Sep/2026
Rockwell Medical USD 232K 199K Jun/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 21.51M 205K Jun/2026
United Therapeutics USD 2.9M 0 Sep/2026
Vertex Pharmaceuticals USD 36M 32.7M Sep/2026